Allergic rhinitis is a highly prevalent chronic inflammatory disorder of the nasal mucosa that poses a significant burden on patients' health and quality of life. Current therapies for allergic rhinitis are unable to reinstate immune homeostasis or are restricted by specific allergens. Potential therapeutic strategies for allergic rhinitis are urgently needed. Mesenchymal stem cells (MSCs) are immune-privileged, have strong immunomodulatory effects, and can be easily isolated from various sources. Thus, MSC-based therapies demonstrate potential for treating inflammatory diseases. Recently, numerous studies have investigated the therapeutic effects of MSCs in animal models of allergic rhinitis. Here, we review the immunomodulatory effects and mechanisms of MSCs on allergic airway inflammation, especially allergic rhinitis, highlight the recent research regarding MSCs in the modulation of immune cells, and discuss the clinical potential of MSC-based therapy for allergic rhinitis.
CITATION STYLE
Wang, M., Zhao, N., Wang, C., Jin, Z. B., & Zhang, L. (2023, June 1). Immunomodulatory properties of mesenchymal stem cells: A potential therapeutic strategy for allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology. John Wiley and Sons Inc. https://doi.org/10.1111/all.15729
Mendeley helps you to discover research relevant for your work.